Aspen has a strong global presence in both emerging and developed countries
with more than 60 established business operations in approximately 50 countries.
Aspen has a strong global presence in both emerging and developed countries
with more than 60 established business operations in approximately 50 countries.

Aspen has a strong global presence in both emerging and developed countries
with more than 60 established business operations in approximately 50 countries.

Aspen’s commitment to creating shareholder value is demonstrated by a compound
annual growth rate of 40% in respect of both gross revenue and EBITA since listing in 1998.
Aspen’s commitment to creating shareholder value is demonstrated by a compound
annual growth rate of 40% in respect of both gross revenue and EBITA since listing in 1998.
Aspen’s commitment to creating shareholder value is demonstrated by a compound
annual growth rate of 40% in respect of both gross revenue and EBITA since listing in 1998.
Aspen’s product offering continues to be enhanced with the thrombosis, anaesthetics,
high potency & cytotoxic and infant nutritional portfolios receiving the highest focus.
Aspen’s product offering continues to be enhanced with the thrombosis, anaesthetics,
high potency & cytotoxic and infant nutritional portfolios receiving the highest focus.
Aspen’s product offering continues to be enhanced with the thrombosis, anaesthetics,
high potency & cytotoxic and infant nutritional portfolios receiving the highest focus.
Aspen builds on the talent of more than 10 000 employees
to drive performance excellence into the next growth horizon.
Aspen builds on the talent of more than 10 000 employees
to drive performance excellence into the next growth horizon.
Aspen builds on the talent of more than 10 000 employees
to drive performance excellence into the next growth horizon.
Responsible corporate citizenship contributions make a significant difference
to society annually through more than 200 socio-economic development projects.
Responsible corporate citizenship contributions make a significant difference
to society annually through more than 200 socio-economic development projects.
Responsible corporate citizenship contributions make a significant difference
to society annually through more than 200 socio-economic development projects.
Stringent environmental management protocols across all its operations
underscore Aspen’s commitment to preserving valuable natural resources.
Stringent environmental management protocols across all its operations
underscore Aspen’s commitment to preserving valuable natural resources.
Stringent environmental management protocols across all its operations
underscore Aspen’s commitment to preserving valuable natural resources.

ABOUT ASPEN

Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality affordable medicines and products.

Aspen has a market capitalisation of approximately US$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks among the top 20 listed companies on this exchange.

SENS ANNOUNCEMENTS

INVESTOR CALENDAR

9 March 2017

Interim results announcement

10 March 2017

Interim results presentation in Cape Town.

Click here for the results presentation.

30 June 2017

Financial year end

14 September 2017

Year end results announcement and presentation in Johannesburg

15 September 2017

Year end results - Cape Town (TBC)

LATEST RESULTS

Aspen interim results commentary

Aspen interim results short form announcement

Aspen interim results presentation

Aspen Integrated Report

Aspen Annual Financial Statements

Aspen Corporate Brochure

INTERNATIONAL

READ MORE

Asia Pacific

READ MORE

South Africa

READ MORE

SUB-SAHARAN AFRICA

READ MORE

International

Aspen’s International business comprises operating subsidiaries in Europe CIS, Latin America, Middle East and North Africa (“MENA”), Canada as well as Mauritian-based AGI, the international commercial business and intellectual property holding company which is also a primary Group trading operation and supply chain hub. Globally branded pharmaceutical products are distributed into multiple territories as well as local brands into selected regions. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville site primarily services Group supply needs and the Bad Oldesloe site is also an important producer for the Group.
Key territories and/or countries supplied to in this region:


Argentina
Brazil
Canada,
Caricam,
Chile
CIS
Colombia
Ecuador
Europe
Mexico
MENA,
Panama
Peru
USA

IMS value of pipeline as at 30 June 2016 anticipated to be launched in:
0 – 2 years
USD0,85 billion


3 – 5 years
USD2,20 billion

Number of products launched from pipeline:
Europe CIS: Nil (2015: Nil)
Latin America: 4 (2015: 43)
Rest of the World: 9 (2015: Nil)

Asia Pacific

Aspen’s Asia Pacific business comprises operations in Australia, New Zealand, the Philippines, Malaysia, Taiwan and Japan. Efforts are underway to establish an operation in China, following Aspen’s recent acquisition of anaesthetic and thrombosis products from AstraZeneca and GSK in this country. These operations supply a diversified portfolio of branded prescription, generic, OTC, consumer and infant nutritional products into Australia and New Zealand and the majority of countries in Asia. Certain tablets, liquids and semi-solids are produced at the Group’s manufacturing site in Melbourne, while other products for customers of this business are sourced from Aspen’s global manufacturing sites and accredited third-party manufacturers.

Key territories and/or countries supplied to in this region:


Australia
China
Hong Kong
Indonesia
Japan
Korea

Malaysia
New Zealand
Philippines
Singapore
Taiwan
Thailand and Vietnam

IMS value of pipeline as at 30 June 2016 anticipated to be launched in:
0 – 2 years
USD1,35 billion


3 – 5 years
USD0,05 billion

Number of products launched from pipeline:
24 (2015: 34)

South Africa

The South African business provides a diverse basket of branded, generic, OTC, consumer health and infant nutritional products which are supplied to pharmacies, retail pharmacy chains, hospitals, clinics, prescribing specialists, dispensing general practitioners, managed healthcare funders and retail stores across the private and public sectors in South Africa.
Key territories and/or countries supplied to in this region:


Botswana
Lesotho
Namibia

South Africa and
Swaziland

IMS value of pipeline as at 30 June 2016 anticipated to be launched in:
0 – 2 years
USD0,21 billion


3 – 5 years
USD0,18 billion

Number of products launched from pipeline:
11 (2015: 9)

Sub-Saharan Africa

Aspen’s presence in SSA is through its wholly owned subsidiaries, Shelys (Tanzania), Beta Healthcare International (Kenya), Beta Healthcare (Uganda) and Aspen Nigeria. Aspen also has a 65% shareholding in Kama (Ghana) and exports products from South Africa into selected territories. While it was agreed to terminate the SSA Collaboration between Aspen and GSK after the 2016 year end close, the SSA Collaboration was an important contributor to the revenue of this region for the 2016 financial year. Aspen uses its own sales representation and distribution infrastructure across the region to supply a range of high quality pharmaceutical products. Aspen has its own operations in Nigeria, Ghana, Kenya, Tanzania, and Uganda, with the rest of the region being serviced through long-standing relationships with local distributors supported by sales representatives. Aspen supplies a range of branded, generic, OTC, consumer health and infant nutritional products into SSA.
Key territories and/or countries supplied to in this region:


Angola
Botswana
Ethiopia
Ghana
Ivory Coast
Kenya
Mauritius

Namibia
Nigeria
Tanzania
Uganda
Zambia and
Zimbabwe

IMS value of pipeline as at 30 June 2016 anticipated to be launched in:
Not covered by IMS

Number of products launched from pipeline:
44 (2015: 19)